Community
TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.
United States
2008 (18 Years)
Last online: No recent activity
Be the first to rate and review this company.
Provided by TrustFinance
Be the first to rate and review this company.
Warning
This company is currently Unproved.
Please be cautious of the potential risks!
License
A Grade License
Issued by globally renowned regulators, these licenses ensure the highest trader protection through strict compliance, fund segregation, insurance, and regular audits. Dispute resolution and adherence to AML/CTF standards further enhance security.
B Grade License
Granted by respected regional regulators, these licenses offer robust safety measures such as fund segregation, financial reporting, and compensation schemes. Though slightly less strict than Tier 1, they provide dependable regional protection.
C Grade License
Issued by regulators in emerging markets, these licenses offer basic protections such as minimum capital requirements and AML policies. Oversight is less stringent, so traders should exercise caution and verify safety measures.
D Grade License
From jurisdictions with minimal oversight, these licenses often lack key protections like fund segregation and insurance. While attractive for operational flexibility, they pose higher risks to traders.
Get to know Loncar Investments
Company Information
Get to know Loncar Investments
Loncar Investments, LLC is a research-focused financial index provider specializing in the biotechnology sector. Founded by investor Brad Loncar, the company's primary mission is to provide investors with exposure to transformative areas of medicine through thoughtfully constructed indexes. Their flagship products are the Loncar Cancer Immunotherapy Index (LCINDX) and the China BioPharma Index (LCHINA), which serve as the underlying basis for publicly traded ETFs (e.g., CNCR and CHNA), allowing the public to invest in a basket of companies leading these innovative fields. The firm is not a direct investment manager or broker but an intellectual property and research company that licenses its indexes to ETF providers.
Industry
Contact
-
-
-
-
Social
Company hasn't updated its information.
Reviews
Total 0
Filter
5 Star
4 Star
3 Star
2 Star
1 Star
Sort by
AI Review analysis
Let’s TrustFinance AI Summarize all the reviews for you.
Provided by TrustFinance AI Analysis
AI Review analysis
Let’s TrustFinance AI Summarize all the reviews for you.
Provided by TrustFinance AI Analysis